ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers. (December 2016) - Zammarchi, F.; Chivers, S.; Williams, D.G.; Adams, L.; Mellinas-Gomez, M.; Tyrer, P.; Corbett, S.; D'Hooge, F.; Dissanayake, S.; Sims, S.; Havenith, K.; Howard, P.W.; et al.